On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

FACT SHEET: President Obama's Precision Medicine Initiative

Building on President Obama's announcement in his State of the Union Address, today the Administration is unveiling details about the Precision Medicine Initiative, a bold new research effort to...

Valeant bids $296M on Dendreon; AstraZeneca pairs with MD Anderson;

@FierceBiotech: Obama wants $215M to kick off 'precision medicine' project. More | Follow @FierceBiotech @JohnCFierce: $ICPT up 38% this a.m., which is nuts. Article | Follow @JohnCFierce...

AstraZeneca, MD Anderson Enter Collaboration to Help Improve Patient Outcomes in Ovarian/ Gynecologic Cancers

WILMINGTON, Del. & HOUSTON, Jan 29, 2015 -- AstraZeneca and The University of Texas MD Anderson Cancer Center today announced a multi-year, strategic research collaboration to conduct multiple,...

Tracon raises $36M in a downsized IPO

Cancer drug developer Tracon Pharmaceuticals pulled in $36 million in an IPO, pricing well below its expected range as it works to get its top drug into late-stage trials.

TRACON Pharmaceuticals Announces Pricing of Initial Public Offering

SAN DIEGO, Jan. 30, 2015 -- TRACON Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 3,600,000 shares of common stock at a price to the public of $10.00 per share....

Obama wants $215M to kick off 'precision medicine' project

President Barack Obama is asking Congress for $215 million to sequence the genomes of 1 million Americans and help develop a new generation of medicines, part of a sweeping plan to accelerate biomedical R&D.

Pfizer bails on a $70M rare disease deal with Repligen

Pfizer is walking away from a $70 million collaboration with Waltham, MA's Repligen, handing back some early-stage treatments for the rare spinal muscular atrophy.

Alexion Pharmaceuticals Inc. (ALXN) Turns to Profit in Q4; Appoints New CEO

Alexion Appoints David L. Hallal as Chief Executive Officer, Effective April 1, 2015 Leonard Bell, M.D. Announces His Plans to Retire as CEO Dr. Bell to Continue as Chairman CHESHIRE,...

bluebird bio Announces Transition of Chief Scientific Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases, today...